Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Guanglin Luo is active.

Publication


Featured researches published by Guanglin Luo.


Tetrahedron Letters | 2002

Microwave-assisted synthesis of aminopyrimidines

Guanglin Luo; Ling Chen; Graham S. Poindexter

Series of mono- or di-substituted aminopyrimidine derivatives were synthesized through microwave-assisted aromatic nucleophilic substitution or Suzuki coupling.


Journal of Medicinal Chemistry | 2012

Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine

Guanglin Luo; Ling Chen; Charles M. Conway; Rex Denton; Deborah Keavy; Laura Signor; Walter Kostich; Kimberley A. Lentz; Kenneth S. Santone; Richard Schartman; Marc Browning; Gary Tong; John G. Houston; Gene M. Dubowchik; John E. Macor

Calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated clinical efficacy in the treatment of acute migraine. Herein, we describe the design, synthesis, and preclinical characterization of a highly potent, oral CGRP receptor antagonist BMS-927711 (8). Compound 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical properties, and shows dose-dependent activity in a primate model of CGRP-induced facial blood flow. Compound 8 is presently in phase II clinical trials.


ACS Medicinal Chemistry Letters | 2012

Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.

Guanglin Luo; Ling Chen; Charles M. Conway; Rex Denton; Deborah Keavy; Michael Gulianello; Yanling Huang; Walter Kostich; Kimberley A. Lentz; Stephen E. Mercer; Richard Schartman; Laura Signor; Marc Browning; John E. Macor; Gene M. Dubowchik

Calcitonin gene-related peptide (CGRP) receptor antagonists have been clinically shown to be effective in the treatment of migraine, but identification of potent and orally bioavailable compounds has been challenging. Herein, we describe the conceptualization, synthesis, and preclinical characterization of a potent, orally active CGRP receptor antagonist 5 (BMS-846372). Compound 5 has good oral bioavailability in rat, dog, and cynomolgus monkeys and overall attractive preclinical properties including strong (>50% inhibition) exposure-dependent in vivo efficacy in a marmoset migraine model.


Tetrahedron Letters | 2002

A novel solid-phase chlorinating reagent for the synthesis of acyl chlorides

Guanglin Luo; Li Xu; Graham S. Poindexter

Cyanuric chloride was loaded onto a modified Wang resin, which was successfully used to convert carboxylic acids to their corresponding acyl chlorides. The formation of acyl chlorides were confirmed by condensation with various amines or alcohols to form the corresponding amides or esters.


Journal of Medicinal Chemistry | 2016

Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.

Guanglin Luo; Ling Chen; Catherine R. Burton; Hong Xiao; Prasanna Sivaprakasam; Carol M. Krause; Yang Cao; Nengyin Liu; Jonathan Lippy; Wendy Clarke; Kimberly Snow; Joseph Raybon; Vinod Arora; Matt Pokross; Kevin Kish; Hal A. Lewis; David R. Langley; John E. Macor; Gene M. Dubowchik

GSK-3 is a serine/threonine kinase that has numerous substrates. Many of these proteins are involved in the regulation of diverse cellular functions, including metabolism, differentiation, proliferation, and apoptosis. Inhibition of GSK-3 may be useful in treating a number of diseases including Alzheimers disease (AD), type II diabetes, mood disorders, and some cancers, but the approach poses significant challenges. Here, we present a class of isonicotinamides that are potent, highly kinase-selective GSK-3 inhibitors, the members of which demonstrated oral activity in a triple-transgenic mouse model of AD. The remarkably high kinase selectivity and straightforward synthesis of these compounds bode well for their further exploration as tool compounds and therapeutics.


Bioorganic & Medicinal Chemistry Letters | 2012

Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group.

Guanglin Luo; Ling Chen; Rita L. Civiello; Sokhom S. Pin; Cen Xu; Walter Kostich; Michelle Kelley; Charles M. Conway; John E. Macor; Gene M. Dubowchik

In our continuing efforts to identify CGRP receptor antagonists that can be dosed orally for the treatment of migraine headache, we have investigated a pyridine bioisosteric replacement of a polar amide portion of a previous lead compound, BMS-694153. Pyridine derivatives were discovered and their SAR was studied. Some of them showed excellent binding potency. However, oral bioavailability was low, even for compounds with good Caco-2 cell permeability.


Organic Letters | 2015

Asymmetric Synthesis of Heterocyclic Analogues of a CGRP Receptor Antagonist for Treating Migraine

Guanglin Luo; Ling Chen; Charles M. Conway; Walter Kostich; John E. Macor; Gene M. Dubowchik

An asymmetric synthesis of novel heterocyclic analogue of the CGRP receptor antagonist rimegepant (BMS-927711, 3) is reported. The cycloheptane ring was constructed by an intramolecular Heck reaction. The application of Hayashi-Miyaura and Ellman reactions furnished the aryl and the amine chiral centers, while the separable diastereomeric third chiral center alcohols led to both carbamate and urea analogues. This synthetic approach was applicable to both 6- and 5-membered heterocycles as exemplified by pyrazine and thiazole derivatives.


Bioorganic & Medicinal Chemistry Letters | 2012

Calcitonin gene-related peptide (CGRP) receptor antagonists: novel aspartates and succinates.

Guanglin Luo; Ling Chen; Sokhom S. Pin; Cen Xu; Charles M. Conway; John E. Macor; Gene M. Dubowchik

Novel aspartate and succinate CGRP full antagonists were identified through core modification of a potent lead CGRP antagonist, BMS-694153. While aspartates were much less active and had a flat SAR, some of the succinates were very potent CGRP full antagonists and matched the potency of BMS-694153. The most potency resides in the S enantiomer as demonstrated through an asymmetric synthesis.


ACS Medicinal Chemistry Letters | 2012

Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.

Shuanghua Hu; Yazhong Huang; Milind Deshpande; Guanglin Luo; Marc Bruce; Ling Chen; Gail K. Mattson; Lawrence G. Iben; Jie Zhang; John W. Russell; Wendy Clarke; John B. Hogan; Astrid Ortiz; Oliver Flint; Andrew Henwood; Qi Gao; Ildiko Antal-Zimanyi; Graham S. Poindexter

A novel class of bicyclo[3.1.0]hexanylpiperazine neuropeptide Y (NPY) Y1 antagonists has been designed and synthesized. Scatchard binding analysis showed these compounds to be noncompetitive with [(125)I]PYY binding to the Y1 receptor. The most potent member, 1-((1α,3α,5α,6β)-6-(3-ethoxyphenyl)-3-methylbicyclo[3.1.0]hexan-6-yl)-4-phenylpiperazine (2) had an IC50 = 62 nM and displayed excellent oral bioavailability in rat (% F po = 80), as well as good brain penetration (B/P ratio = 0.61). In a spontaneous nocturnal feeding study with male Sprague-Dawley rats, 2 significantly reduced food intake during a 12 h period.


Journal of Organic Chemistry | 2017

Asymmetric Synthesis of the Major Metabolite of a Calcitonin Gene-Related Peptide Receptor Antagonist and Mechanism of Epoxide Hydrogenolysis

Guanglin Luo; Ling Chen; Charles M. Conway; Walter Kostich; Benjamin M. Johnson; Alicia Ng; John E. Macor; Gene M. Dubowchik

An asymmetric synthesis of the major metabolite of the calcitonin gene-related peptide recepotor antagonist BMS-846372 is presented. The variously substituted cyclohepta[b]pyridine ring system represents an underexplored ring system and showed some unexpected chemistry. Reactivities of epoxide and ketone functional groups on the cycloheptane ring were extensively controlled by a remote bulky TIPS group. The rate difference of the hydrogenolysis between two diastereomeric epoxide intermediates shed some light on the mechanism of epoxide hydrogenolysis, and further, deuterium labeling studies revealed more mechanistic details on this well-known chemical transformation for the first time.

Collaboration


Dive into the Guanglin Luo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge